54.54
+1.675(+3.17%)
Currency In USD
| Previous Close | 52.86 |
| Open | 53.15 |
| Day High | 54.54 |
| Day Low | 53.15 |
| 52-Week High | 54.6 |
| 52-Week Low | 21.72 |
| Volume | 1.03M |
| Average Volume | 2.51M |
| Market Cap | 10.43B |
| PE | -13.2 |
| EPS | -4.13 |
| Moving Average 50 Days | 50.15 |
| Moving Average 200 Days | 39.3 |
| Change | 1.68 |
If you invested $1000 in BridgeBio Pharma, Inc. (BBIO) since IPO date, it would be worth $1,979.49 as of October 06, 2025 at a share price of $54.535. Whereas If you bought $1000 worth of BridgeBio Pharma, Inc. (BBIO) shares 5 years ago, it would be worth $1,385.9 as of October 06, 2025 at a share price of $54.535.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM
GlobeNewswire Inc.
Sep 28, 2025 3:15 PM GMT
- By Month 1, numerically fewer cumulative events were observed with acoramidis compared to placebo - Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction (p<0.0001)
BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025
GlobeNewswire Inc.
Sep 22, 2025 11:30 AM GMT
PALO ALTO, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one late breaking clinical trials
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
GlobeNewswire Inc.
Sep 06, 2025 6:30 PM GMT
- 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on conventional therapy at baseli